EMA Reviews Studies on Ozempic's Risk of Eye Condition

The European Medicines Agency (EMA), the EU's drug regulator, has announced a review of two studies suggesting a link between Novo Nordisk's popular diabetes drug, Ozempic, and a rare eye condition.

Overview of the Eye Condition

The condition, known as nonarteritic anterior ischemic optic neuropathy, results from reduced blood flow to the optic nerve, leading to vision loss.

Research Findings

Studies from the University of Southern Denmark suggest that patients using Ozempic may face an increased risk of developing this eye condition. In light of these findings, Novo Nordisk emphasized its commitment to addressing all reports of adverse events linked to its medications.

However, Novo Nordisk noted that the studies did not definitively prove a cause-and-effect relationship between semaglutide, Ozempic's active ingredient, and the eye issue. Semaglutide is also found in Wegovy, another Novo Nordisk product aimed at weight loss.

Company Statement

The company's internal safety assessment and review indicated that the benefit-risk profile of semaglutide remains unchanged.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.